*Clinical sensitivity using the recommended ratio cut-off of 2 for the DELFIA® procedure with 95% confidence intervals. GSP®/DELFIA® Anti-SARS-CoV-2 IgG kit was tested in two clinical laboratories in Finland using the DELFIA® procedure with samples 21 days or more from symptoms onset.
The PerkinElmer® GSP®/DELFIA® Anti-SARS-CoV-2 IgG kit is intended for the qualitative detection of human antibodies of the immunoglobulin class IgG against SARS-CoV-2 in human blood specimens dried on filter paper and in human serum as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.
Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.